Healthcare of Ontario Pension Plan Trust Fund Has $18.81 Million Position in Danaher Co. (NYSE:DHR)

Healthcare of Ontario Pension Plan Trust Fund lifted its position in Danaher Co. (NYSE:DHR) by 48.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 67,639 shares of the conglomerate’s stock after acquiring an additional 22,205 shares during the period. Healthcare of Ontario Pension Plan Trust Fund’s holdings in Danaher were worth $18,805,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of DHR. CarsonAllaria Wealth Management Ltd. acquired a new position in shares of Danaher in the 2nd quarter valued at $25,000. nVerses Capital LLC acquired a new position in Danaher in the second quarter valued at about $25,000. MidAtlantic Capital Management Inc. acquired a new stake in shares of Danaher during the third quarter worth about $40,000. MFA Wealth Advisors LLC bought a new position in shares of Danaher during the 2nd quarter valued at about $51,000. Finally, Financial Connections Group Inc. acquired a new position in shares of Danaher in the 2nd quarter valued at approximately $51,000. Institutional investors own 79.05% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have commented on DHR shares. Evercore ISI raised their target price on shares of Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. TD Cowen boosted their price objective on shares of Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a research report on Wednesday, October 23rd. Robert W. Baird reduced their target price on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a research note on Wednesday, October 23rd. UBS Group dropped their price target on Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a research note on Wednesday, October 23rd. Finally, Royal Bank of Canada reduced their price objective on Danaher from $333.00 to $311.00 and set an “outperform” rating for the company in a research report on Wednesday, October 23rd. Five analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat.com, Danaher has a consensus rating of “Moderate Buy” and an average target price of $287.16.

Danaher Stock Performance

Shares of DHR stock opened at $238.83 on Friday. The company has a market cap of $172.50 billion, a price-to-earnings ratio of 45.58, a price-to-earnings-growth ratio of 4.37 and a beta of 0.85. Danaher Co. has a 52 week low of $215.68 and a 52 week high of $281.70. The firm has a 50 day moving average of $255.25 and a 200-day moving average of $259.52. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, topping the consensus estimate of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The company had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. During the same period in the previous year, the firm posted $2.02 earnings per share. The firm’s revenue for the quarter was up 3.1% on a year-over-year basis. On average, equities analysts forecast that Danaher Co. will post 7.5 earnings per share for the current year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, October 25th. Shareholders of record on Friday, September 27th were paid a $0.27 dividend. The ex-dividend date was Friday, September 27th. This represents a $1.08 annualized dividend and a yield of 0.45%. Danaher’s dividend payout ratio (DPR) is 20.61%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.